N-Phenaethyl-3,3-diphenyl-propylamin

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Phenaethyl-3,3-diphenyl-propylamin
• 英文别名: 3,3-diphenyl-N-(2-phenylethyl)propan-1-amine
• 化学式: C₂₃H₂₅N
• 分子量: 315.458
• InChiKey: AMHIHFBLZRZNPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3-二苯基丙酸 在 palladium on barium sulfate 喹啉 、 氯化亚砜 、 氢气 、 sulfur 作用下， 以 xylene 为溶剂， 生成 N-Phenaethyl-3,3-diphenyl-propylamin
  参考文献：
  名称：

  二苯丙胺衍生物。I.N-取代的3，3-二苯基丙烯酰胺。

  摘要：

  DOI：

  10.1021/jm00335a011

文献信息

• Collino, Bollettino Chimico Farmaceutico, 1969, vol. 108, # 6, p. 355 - 367
  作者：Collino

  DOI：——

  日期：——
• Computational Design and Discovery of “Minimally Structured” hERG Blockers
  作者：Andrea Cavalli、Rosa Buonfiglio、Cristina Ianni、Matteo Masetti、Luisa Ceccarini、Rachel Caves、Michael W. Y. Chang、John S. Mitcheson、Marinella Roberti、Maurizio Recanatini

  DOI：10.1021/jm201194q

  日期：2012.4.26

  Molecular knowledge of hERG blocking liability can offer the possibility of optimizing lead compounds in a way that eliminates potentially lethal side effects. In this study, we computationally designed, synthesized, and tested a small series of "minimally structured" molecules. Some of these compounds were remarkably potent against hERG (6, IC50 = 2.4 nM), allowing us to identify the minimal structural requirements for hERG blocking liability.
• INKLUSIONSCOMPLEXE VON N-(1-PHENYLÄTHYL)-3,3-DIPHENYLPROPYLAMIN BZW. DESSEN HYDROCHLORID MIT CYCLODEXTRIN, VERFAHREN ZUR HERSTELLUNG DIESER INKLUSIONSKOMPLEXE SOWIE DIESE INKLUSIONSKOMPLEXE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE
  申请人：CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT.

  公开号：EP0078820B1

  公开（公告）日：1987-12-09
• [EN] METHOD FOR TREATING ANDROGEN-RELATED CONDITIONS<br/>[FR] METHODE DE TRAITEMENT D'AFFECTIONS LIEES AUX ANDROGENES
  申请人：MERCK & CO INC

  公开号：WO2000018402A1

  公开（公告）日：2000-04-06

  The present invention provides for the combined use of 5α-reductase inhibitors together with calcium channel blockers for the treatment of benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, hematuria, and other androgen related disorders, including prostatitis and the prevention of prostate cancer. This invention provides a method of treatment which is useful in the treatment of benign prostatic hyperplasia, prostatitis, and/or the prevention and treatment of prostatic cancer, as well as in the treatment of prostatitis and hematuria. This invention also provides a pharmaceutical composition which is useful in the treatment of benign prostatic hyperplasia, prostatitis, hematuria and/or the prevention and treatment of prostatic cancer, wherein the pharmaceutical composition comprises the combination of a 5α-reductase inhibitor and a calcium channel blocking agent.
• [EN] 3,3-DIPHENYL-N-(1-PHENYLETHYL) PROPAN-1 -AMINE : AS A NEW SELECTIVE LIGAND OF THE SIGMA-1 RECEPTORS, WITH ANTI-APOPTOTIC (CYTOPROTECTIVE) PROPERTIES AND PROTOTYPICAL ANTICANCER ACTIVITY<br/>[FR] 3,3-DIPHÉNYL-N-(1-PHÉNYLÉTHYL)PROPAN-1-AMINE : NOUVEAU LIGAND SÉLECTIF DES RÉCEPTEURS SIGMA-1, AYANT DES PROPRIÉTÉS ANTI-APOPTOTIQUES (CYTOPROTECTRICES) ET UNE ACTIVITÉ ANTICANCÉREUSE PROTOTYPIQUE
  申请人：VAMVAKIDES ALEXANDRE

  公开号：WO2013104933A1

  公开（公告）日：2013-07-18

  3,3-diphenyl-N-(l-phenylethyl) propan-l-amine (fendiline): as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytopro- tective) properties and prototypical anticancer activity. This invention concerns the prototypical profile of selective sigma-1 ligand and the putative therapeutical properties of the compound 3,3-diphenyl-N-(l-phenylethyl) propan-l-amine (DPPA) and its pharmaceutically acceptable salts, with cytoprotective activity, more specifically for neurons against the neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) via their anti-apoptotic properties induced by their selective sigma-1 agonism. Concerning the cancer cells, DPPA e hibited pro-apoptotic properties associated with neuroprotective activity originating a prototypical anticancer profile consisting in synergistical association with the clinically used anticancer drugs with its analgesic and neuroprotective activities antagonizing the neuropathic pain induced by the later.